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show corticotherapy to be beneﬁcial in this patient group
[1]. In fact, aswe discussed in the article the haemodynam-
ic response to steroids may be independent of the degree
of adrenal insuﬃciency and therefore may represent a
purely pharmacological eﬀect. This is supported by the re-
cent data from the CORTICUS study group which
showed that patients with septic shock treated with corti-
costeroids have faster resolution of shock which is inde-
pendent of the response to adrenal stimulation but also
have an increased incidence of superinfection and new
septic shock [2]. Similar to the report by McCaughan
et al. we have also found a high incidence (53%) of adrenal
insuﬃciency in cirrhotic patients [3,4]. It is therefore un-
clear whether the adrenal insuﬃciency observed in criti-
cally ill liver patients is a pre-existing condition or
related to the critical illness per se. Given that there ap-
pears to be potential for adverse outcome with corticoste-
roid therapy we agree with Professor McCaughan that
controlled clinical trials examining the role of corticoste-
roid supplementation in cirrhotic patients with critical ill-
ness and adrenal insuﬃciency are urgently needed.References
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It is with great interest that we read the article by the
Spanish Acute HCV study group identifying hospital
admission as a signiﬁcant risk factor for acquiring HCV
infection in Spain [1].While it iswell known that the trans-
mission of HCV may occur through medical procedures
in countries with a low or medium human development
index [2], infectionwithHCVduring inpatient or ambula-
tory treatment is thought to be uncommon in the devel-
oped countries. This is supported by the fact that HCV
is by far less infectious than HBV. Moreover, we have re-
cently reported that the risk of acquiring HCV by a nee-
dlestick injury is an extremely rare event and that the
risk of acute HCV infection after injury with an HCV-
contaminated needle in Europe is below 0.5% [3].
At ﬁrst view, these data are in contrast to the rather
high proportion of nosocomial HCV acquisition of 67%
reported by the Spanish Acute HCV study group.
Although this high proportion might be partially ex-
plained by the fact that patients were referred for antiviral
treatment, the data are in line with other reports from
Italy [4], France [5], and the USA [6]. We have analyzed
the data of the German National Acute HCV studies I
[7] and II [8] and the currently ongoing acute HCV-IIIstudy for the possible sources of HCV infection. We also
included the data of 31 patients who did not fulﬁl the
inclusion criteria for therapy in the Hep-Net Acute-
HCV-III study. Overall, the Hep-Net cohort consists of
254 patients with acute hepatitis C (November 15,
2007). Among those, hospital admission was a less impor-
tant risk factor as compared to the Spanish experience.
Only 38 (15%) of our acute hepatitis C patients reported
a medical procedure as the most likely risk factor for hav-
ing acquired HCV. The table lists the type of procedures
in these cases. The majority of those consisted of hospital
admissions for surgery (n = 30 cases). Other invasive pro-
cedures including dental treatment were present in only 4
cases. Medical procedures were signiﬁcantly more often
the probable cause of infection in patients older than 30
years of age (p = 0.002 vs. patients younger than 30 years)
but not associatedwith disease severity or time fromexpo-
sure to the onset of symptoms. Another, somewhat wor-
rying ﬁnding was that still more than 25% of patients
were not aware of any obvious source of infection (see Ta-
ble 1).
Although medical procedures as a risk factor for HCV
infection seem to be less important in Germany than in
Spain, our ﬁndings are still alarming. Screening for
Katja Deterding 1
Johannes Wiegand 1,2
Norbert Gru¨ner 3
Heiner Wedemeyer 1,*
1Department of Gastroenterology,
Hepatology and Endocrinology,
Hannover Medical School,
Hannover, Germany
2Department of Internal Medicine II,
University of Leipzig, Germany
3Medical Department II and Institute for Immunology,
Ludwig-Maximillians-University,
Munich, Germany
E-mail address: Wedemeyer.Heiner@mh-hannover.de
(H. Wedemeyer).
doi:10.1016/j.jhep.2008.03.001
Table 1
Potential sources of HCV infection in 254 patients with acute hepatitis
recruited in the Hep-Net acute HCV-database
Risk factor No. (%) of patients
Intravenous drug abuse 41 (16%)
Medical procedure 38 (15%)
Hospitalization 1
Surgery 30
Blood transfusion 2
Dental treatment 1
Other invasive procedures 3
Acupuncture 1
Needlestick injury 34 (13%)
Tattoo and/or body piercing 6 (2.3%)
Sexual contact/promiscuity 56 (22%)
Other 9 (3.5%)
Unknown 68 (27%)
1020 Letters to the Editor / Journal of Hepatology 48 (2008) 1018–1021HCV infection should not only be recommended for pa-
tients at risk such as patients under haemodialysis. The
available data suggest that all the individuals undergoing
invasive medical procedures should be tested for anti-
HCV since 0.5% to 1.5%of the European population is in-
fected with HCV and thus representing a potential source
for HCV transmission. As up to one-third of chronic hep-
atitis C patients with signiﬁcant HCV viremia do present
with normal liver enzymes, only testing for anti-HCVwill
be suﬃcient to identify HCV-infected individuals.
In summary, medical treatment per se represents a
signiﬁcant risk factor for HCV infection – even in well
developed countries. Thus, we strongly support the con-
clusions by the Spanish Acute HCV Study Group that
the strict adherence to universal precaution guidelines
is urgently warranted.
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study. Hepatology 2006;43:250–256.Nosocomial acquisition of the hepatitis C virusTo the Editor:
We would like to thank Deterding et al. for their
comments to our recently published article [1]. We
essentially agree with their observations. As they state,
it is possible that the high proportion of patients who
acquired HCV in a nosocomial setting in our study is
partially explained for by the fact that these patients
were referred to a tertiary hospital. However, other pos-
sible explanations are the slightly higher prevalence of
chronic HCV infection in Spain, as compared to Ger-many, and the potential diﬀerences in the health care
systems of both countries [2]. In fact, it would be impor-
tant to analyze if the number of patients (or workload)
assigned per nurse, as well as the total hours of nursing
care provided by registered nurses instead of licensed
practical-nurses are diﬀerent in both countries. There
are data showing a clear relationship between the hours
of care given by registered nurses and the shorter length
of stay and lower rates of infections in medical and sur-
gical patients [3,4]. Thus, the workload and professional
